Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients Aged 65 Years or Older With Chronic Hepatitis C: A Pooled Analysis of Phase 2 and 3 Clinical Trials

被引：0
|
作者：
Foster, Graham R. [1 ]
Kopecky-Bromberg, Sarah [2 ]
Lei, Yang [2 ]
Mensa, Federico J. [2 ]
机构：
[1] Queen Mary Univ London, Hepatol Unit, London, England
[2] AbbVie Inc, N Chicago, IL USA
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1188
引用
收藏
页码：640A / 641A
页数：2
相关论文
共 50 条
  • [1] Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older
    Foster, Graham R.
    Asselah, Tarik
    Kopecky-Bromberg, Sarah
    Lei, Yang
    Asatryan, Armen
    Trinh, Roger
    Zadeikis, Neddie
    Mensa, Federico J.
    PLOS ONE, 2019, 14 (01):
  • [2] Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials
    Heo, Jeong
    Kim, Yoon Jun
    Lee, Jin-Woo
    Kim, Ji Hoon
    Lim, Young-Suk
    Han, Kwang-Hyub
    Jeong, Sook-Hyang
    Cho, Mong
    Yoon, Ki Tae
    Bae, Si Hyun
    Crown, Eric D.
    Fredrick, Linda M.
    Alami, Negar Niki
    Asatryan, Armen
    Kim, Do Hyun
    Paik, Seung Woon
    Lee, Youn-Jae
    GUT AND LIVER, 2021, 15 (06) : 895 - 903
  • [3] Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older
    Komaki, Yuri
    Ozono, Yoshinori
    Nakamura, Kenichi
    Iwakiri, Hisayoshi
    Hasuike, Satoru
    Sueta, Mitsue
    Miike, Tadashi
    Yamamoto, Shojiro
    Uto, Hirofumi
    Kusumoto, Kazunori
    Ochiai, Toshimasa
    Kato, Junya
    Komada, Naoto
    Kuroki, Kazuo
    Eto, Toshiharu
    Shigehira, Masafumi
    Hirono, Shuichi
    Nagata, Kenji
    Kawakami, Hiroshi
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [4] Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older
    Yuri Komaki
    Yoshinori Ozono
    Kenichi Nakamura
    Hisayoshi Iwakiri
    Satoru Hasuike
    Mitsue Sueta
    Tadashi Miike
    Shojiro Yamamoto
    Hirofumi Uto
    Kazunori Kusumoto
    Toshimasa Ochiai
    Junya Kato
    Naoto Komada
    Kazuo Kuroki
    Toshiharu Eto
    Masafumi Shigehira
    Shuichi Hirono
    Kenji Nagata
    Hiroshi Kawakami
    BMC Gastroenterology, 22
  • [5] Efficacy and safety of glecaprevir/pibrentasvir in patients with hepatitis C virus infection aged ≥75 years
    Kinoshita, Akiyoshi
    Koike, Kazuhiko
    Mizuno, Yusuke
    Ogata, Itsuro
    Kobayashi, Yutaro
    Hasegawa, Kiyoshi
    Shiraishi, Koichi
    Yoshida, Hideo
    Nakata, Ryo
    Yamada, Norie
    Yasuda, Kiyomi
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2020, 20 (06) : 578 - 583
  • [6] Safety and efficacy of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C in patients aged 65 years or older: a retrospective analysis of phase 3 studies
    Sulkowski, M.
    Foster, G.
    Shiffman, M.
    Byrne, S.
    Wolf, J.
    Grabowski, C.
    McNally, J.
    Brainard, D.
    Etzkorn, K.
    Sheikh, A.
    Feld, J.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S719 - S719
  • [7] SAFETY AND EFFICACY OF SOFOSBUVIR/ VELPATASVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS AGED 65 YEARS OR OLDER: A RETROSPECTIVE ANALYSIS OF PHASE 3 STUDIES
    Shiffman, Mitchell L.
    Sulkowski, Mark S.
    Foster, Graham R.
    Byrne, Sean
    Wolf, John
    Grabowski, Chester
    McNally, John
    Brainard, Diana
    Etzkorn, Kyle P.
    Sheikh, Aasim
    Feld, Jordan J.
    GASTROENTEROLOGY, 2017, 152 (05) : S1097 - S1097
  • [8] Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
    Krishnan, Preethi
    Pilot-Matias, Tami
    Schnell, Grega
    Tripathi, Rakesh
    Ng, Teresa I.
    Reisch, Thomas
    Beyer, Jill
    Dekhtyar, Tatyana
    Irvin, Michelle
    Xie, Wangang
    Larsen, Lois
    Mensa, Federico J.
    Collins, Christine
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (10)
  • [9] Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic Hepatitis C aged 75 years or older: A multicenter study
    Pugliese, N.
    Calvaruso, V.
    Masarone, M.
    D'Ambrosio, R.
    Battistella, S.
    Licata, A.
    Persico, M.
    Anolli, M. P.
    Distefano, M.
    Petta, S.
    Russo, F. P.
    Di Marco, V.
    Aghemo, A.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 : S26 - S26
  • [10] Efficacy and Safety of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Patients: A Systematic Review and Meta-analysis
    Xu, Hong-Qin
    Wang, Chun-Guang
    Xiao, Peng
    Gao, Yan-Hang
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2020, 8 (03) : 267 - 276
12345